Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.52 |
| ▸ | NCF1 | P14598 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 2/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | NCK1 | P16333 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28165427 | 0.98 | BACE1 (0.50) | BACE1NCF1NOS2PLAUNCK1 | |
| SCHEMBL10615118 | 0.82 | BACE1 (0.52) | BACE1NCF1NOS2PLAUNCK1 | |
| SCHEMBL30695314 | 0.77 | IMPDH2 (0.42) | IMPDH2PRKCZLMNACYP1A2CYP3A4 | |
| SCHEMBL3064494 | 0.77 | IMPDH2 (0.42) | IMPDH2PRKCZLMNACYP1A2CYP3A4 | |
| SCHEMBL1899820 | 0.76 | NPC1 (0.47) | IMPDH2PRKCZLMNACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL27831443 | 0.76 | IMPDH2 (0.41) | IMPDH2PRKCZLMNACYP1A2CYP3A4 | |
| SCHEMBL276050 | 0.73 | PDE3B (0.39) | IMPDH2PRKCZLMNACYP1A2CYP3A4 | |
| SCHEMBL276051 | 0.73 | KDM4E (0.41) | IMPDH2PRKCZ | |
| SCHEMBL20019250 | 0.73 | CYP1A2 (0.35) | IMPDH2PRKCZLMNACYP1A2CYP3A4 | |
| SCHEMBL4291880 | 0.73 | PDE3B (0.35) | IMPDH2HASPINPRKCZLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200035418-A1 | PASSIVATION OF DEFECTS IN PEROVSKITE MATERIALS FOR IMPROVED SOLAR CELL EFFICIENCY AND STABILITY | NUTECH VENTURES | 2020-01-30 | — | — | US | claimed |
| WO-2018152494-A1 | PASSIVATION OF DEFECTS IN PEROVSKITE MATERIALS FOR IMPROVED SOLAR CELL EFFICIENCY AND STABILITY | NUTECH VENTURES (US) | 2018-08-23 | — | — | WO | claimed |
| EP-2802590-A1 | THIENOPYRIMIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2014-11-19 | — | — | EP | claimed |
| WO-2013104575-A1 | THIENOPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | claimed |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4656602-A2 | MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES | Entegris, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12459956-B2 | Heterobicyclic carboxamides and uses thereof | ALCON INC. (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| CN-1414952-A | Heterocyclic compounds having sulfonic acid | EISAI CO LTD (JP) | 2003-04-30 | — | — | CN | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-4038391-A | TRANQUILIZERS, ANTICONVULSANTS | RHONE-POULENC S.A. (FR) | 1977-07-26 | — | — | US | disclosed |
| US-4016274-A | TRANQUILIZERS AND ANTICONVULSANT AGENTS | RHONE-POULENC S.A. (FR) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BACE1 759/4885NCF1 2891/4885NOS2 3629/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BACE1 759/4885NCF1 2891/4885NOS2 3629/4885 |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | SYK, BTK, LCK | BACE1 3388/4885NCF1 393/4885NOS2 1193/4885 |
| US-12459956-B2 | Heterobicyclic carboxamides and uses thereof | UACA, PHKG2, CCAR2 | BACE1 2843/4885NCF1 2150/4885NOS2 1863/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | BACE1 1341/4885NCF1 2061/4885NOS2 4014/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | BACE1 3606/4885NCF1 2852/4885NOS2 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.